Hepatitis C
Conditions
Keywords
Hepatitis C, anti-E1E2 antibodies, cirrhosis, triple therapy
Brief summary
The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy.
Interventions
OTHERTriple therapy
Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HCV patients with compensated cirrhosis (Child-Pugh A) * HCV genotype 1 * non-responders to a previous course of interferon (IFN)/ribavirin * receiving boceprevir or telaprevir
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with positive anti-E1E2 antibody level at treatment initiation | Baseline (initiation of treatment) | Anti-E1E2 antibody levels were determined as previously described (Ndongo et al. Hepatology 2010;52:1531-42) using optical densities obtained after dilution of patients' serum samples at 1/250 and 1/500. Samples with anti-E1E2 levels above 950 (OD value× 1000) were considered positive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kinetic of Quantification of hepatitis C viral load (HCV RNA) | baseline (initiation of treatment), at week 4, 12, 24, 36, 48 of therapy, at 12 weeks after the end of treatment. | Viral load was assessed at baseline (initiation of treatment), and at week 4, 12, 24, 36, and 48 of therapy and 12 weeks after the end of treatment. |
Countries
France
Outcome results
None listed